Regierer et al reported the B2 Prognostic Index (B2PI) for predicting the outcome for a woman with metastatic breast cancer. The authors are from multiple institutions in Germany.
Patient selection: metastatic breast cancer
Parameters:
(1) metastasis-free interval in years
(2) hormone receptor status
(3) liver metastasis
(4) malignant effusion
(5) brain metastasis
(6) bone metastases
(7) bone marrow metastasis
(8) soft tissue metastasis
(9) lung metastasis
Parameter |
Finding |
Points |
metastasis-free interval |
<= 2 years |
3 |
|
> 2 years |
0 |
hormone receptor status |
negative |
8 |
|
positive |
0 |
liver metastasis |
absent |
0 |
|
present |
7 |
malignant effusion |
absent |
0 |
|
present |
4 |
brain metastasis |
absent |
0 |
|
present |
8 |
bone metastasis |
absent |
0 |
|
present |
4 |
bone marrow metastasis |
absent |
0 |
|
present |
10 |
soft tissue metastasis |
absent |
0 |
|
present |
4 |
lung metatasis |
absent |
0 |
|
present |
4 |
total score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: 0
• maximum score: 52
Total Score |
Risk Group |
5-Year Survival |
<= 8 |
low |
41% |
9 to 14 |
intermediate |
27% |
>= 15 |
high |
10% |
Specialty: Hematology Oncology